替罗非班联合硝苯地平控释片、曲美他嗪治疗顽固性心绞痛的疗效观察

全文: PDF(2001 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨替罗非班联合硝苯地平控释片、曲美他嗪治疗顽固性心绞痛的临床疗效，旨在为临床选择合理有效的治疗方法提供参考。方法将某院收治的顽固性心绞痛患者分为对照组和观察组，对照组采用常规对症治疗，在观察组常规对症治疗基础上采用替罗非班联合硝苯地平控释片、曲美他嗪治疗。比较2组患者的疗效差异。结果治疗前2组患者的心绞痛症状评分差异无显著性(P>0.05);治疗后2组患者的心绞痛症状评分均明显下降(P<0.05)，且观察组明显低于对照组，差异有显著性(P<0.05)。治疗后对照组显效29例，有效12例，无效13例，总有效率82.0%;观察组显效37例，有效11例，无效2例，总有效率96.0%;观察组总有效率明显高于对照组，差异有显著性(P<0.05)。结论替罗非班联合硝苯地平控释片、曲美他嗪治疗顽固性心绞痛能够有效改善临床症状，效果显著。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：顽固性心绞痛, 替罗非班, 硝苯地平控释片, 曲美他嗪

Abstract：Objective Study tirofiban combined with nifedipine controlled release tablets, QuMei Trimetazidine clinical curative effect of trimetazidine on patients with refractory angina pectorisMethods The patients with refractory angina were divided into control group and observation group. The control group was given routine symptomatic treatment, patients in the observation group were treated with tirofiban combined with nifedipine controlled release tablets, QuMei Trimetazidine. Compare the difference of curative effect between the two groups of patients.Results The effect of the observation group was better than that of the control group(P＜0.05). There was no significant difference in serum OX40L, sICAM-1 and hs-CRP levels in the two groups before treatment (P>0.05). The serum levels of OX40L, sICAM-1 and hs-CRP in the observation group were significantly lower than those in the control group after treatment(P<0.05). There was no significant difference in the scores of angina pectoris in the two groups before treatment (P>0.05). After treatment, the observation group of patients with angina pectoris symptom score was significantly better than the control group (P<0.05).Conclusion Tirofiban combined with nifedipine controlled release tablets, QuMei trimetazidine in the treatment of refractory angina pectoris can effectively inhibit the formation of thrombus, and improve the clinical symptoms. Curative effect is distinct, and it is worth clinical promotion.

Key words： refractory angina tirofiban nifedipine controlled release tablets QuMei Trimetazidine

出版日期: 2016-09-14

基金资助:邢台市科技计划项目(No.2014ZC174)

作者简介: 王宏斌(1974-)，男，大学本科，副主任医师。从事心脏内科疾病临床诊疗工作。

引用本文:

王宏斌. 替罗非班联合硝苯地平控释片、曲美他嗪治疗顽固性心绞痛的疗效观察[J]. 解放军预防医学杂志, 2016, 34(4): 564-565.
WANG Hongbin. Tirofiban combined with Nifedipine Controlled Release Tablets, he QuMei in the treatment of refractory angina pectoris. Journal of Preventive Medicine of Chinese People's Liberation Army, 2016, 34(4): 564-565.

链接本文:

http://manu37.magtech.com.cn/Jwk_jsyxkx/jfj/CN/ 或 http://manu37.magtech.com.cn/Jwk_jsyxkx/jfj/CN/Y2016/V34/I4/564

(1) 梅春龙.血瘀方联合常规药物治疗不稳定型心绞痛疗效观察(J).现代中西医结合杂志,2012,21(10):1078.
(2) 张水定.丹参酮联合尿激酶治疗顽固性不稳定型心绞痛24例(J).现代中西医结合杂志,2011,20(14):1771.
(3) 祝志云,王梦洪,段文峰.替罗非班治疗不稳定型心绞痛的临床观察(J).南昌大学学报(医学版),2011,51(2)55.
(4) 何应妮.尼可地尔治疗微血管性心绞痛的疗效及对血管内皮功能的影响(J).现代中西医结合杂志,2015,24(19):2134.
(5) 周青松,童金英,潘荣华.替罗非班在急性冠脉综合征中的临床应用(J).江西医药,2010,45(71):665.
(6) 张清芬,袁华兵,倪艳辉,等.尼可地尔联合单硝酸异山梨酯缓释片治疗老年顽固性不稳定型心绞痛临床研究(J).河北医药,2015(24):3767.
(7) 刘小丽.顽固性不稳定型心绞痛应用替罗非班的临床研究(J).医学信息,2014(7):3.
(8) 陈贝健,杨红,李国庆,等.半量替罗非班在老年冠状动脉旁路移植术前过渡期应用的疗效及安全性分析(J).中华老年多器官疾病杂志,2015,14(9):700.
(9) 吴焱贤,吴赛珠,钟建开,等.冠状动脉内注射替罗非班对急诊介入治疗中慢血流现象的临床疗效(J).中华老年心脑血管病杂志,2013,15(2):139.